Item 7.01 Regulation FD Disclosure.

On January 10, 2023, Pieris Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the phase 1 study of SGEN-BB228/PRS-346, a novel bispecific antibody-Anticalin molecule (Mabcalin™) that is designed to provide a potent costimulatory bridge between tumor-specific T cells and CD228 expressing tumor cells. A copy of the press release issued by the Company is furnished hereto as Exhibit 99.1.

The information set forth under this "Item 7.01. Regulation FD Disclosure," including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for any purpose, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing except as shall be expressly set forth by specific reference in such filing.


--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release, dated January 10, 2023.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses